
Dr. Timothy Scott Blackwell
Vanderbilt-Ingram Cancer Center
doctor matchDirector, Division of Allergy, Pulmonary, and Critical Care Medicine and the Center for Lung Research
Lung Cancer, Malignant Mesothelioma
University of Alabama-Birmingham
Washington University Medical Center
Blackwell has authored or co-authored nearly 200 publications, most of them on various lung cancers and treatments and trials for diseases of the lungs.
Bio
What if doctors could predict which patients would get lung cancer and mesothelioma, find these diseases even before tumors grow, and stop them in their tracks before they do irreparable damage?
That's exactly what Timothy Scott Blackwell, M.D., a lung disease expert at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, has in mind. And it isn't so far out of reach.
Blackwell, a professor of medicine, cancer biology and cell and development biology, as well as the director for the university's Center for Lung Research, is part of a large team of doctor-scientists analyzing lung diseases at the cellular level to see how they progress and respond to potential treatments.
Specifically, Blackwell and his colleagues are zeroing in on the connection between runaway inflammation and the development of cancer and other lung diseases like malignant pleural mesothelioma.
Inflammation is an immune system response to any invader, including viruses, bacteria or even toxic substances like asbestos. In the lungs, inflammation causes the formation of mucus and an increased blood supply. Although this is a normal process, if long-term inflammation goes untreated or doesn’t respond to treatment, it eventually causes scarring and lung diseases. And, it is a perfect environment for tumors to grow.
Blackwell and his colleagues are studying the chemical NF-kappa-B and similar substances within immune system cells that signal the inflammation response to activate and promote tumor growth. The idea is to find ways to shut off or interrupt this signal, stopping unchecked inflammation as well as tumor formation and proliferation.
In addition, Blackwell and other researchers at Ingram Cancer Center are looking for biological compounds inside the body that might predict who will and won't get cancer. His team has been analyzing tissue from both smokers and non smokers to find cellular differences between each group so that researchers will not only be able to screen patients, but also tailor treatments to people who may get sick.
In addition to participating in research at Ingram, Blackwell is a board-certified internist specializing in diagnosing and treating lung diseases. Furthermore, he is a member of Ingram’s mesothelioma, small cell lung cancer and non-small cell lung cancer teams that include pulmonologists, medical and surgical oncologists and thoracic surgeons.
-
05/24/2012 -
One of the biggest asbestos-abatement jobs ever done in Buffalo, New York, is being handled now by a local company with a history of asbestos-related ..
-
05/23/2012 -
A new class of anti-cancer drugs is nearing the clinical trial phase and may eventually be available for treatment of aggressive diseases like pancrea ..
-
05/23/2012 -
School districts all across America have been wrestling in recent years with the task of removing and disposing of toxic asbestos from older buildings ..





